In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.
Form Bio’s Chief Strategy Officer, Claire Aldridge, is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
New integration delivers 52% cost savings and 88% time savings in computational execution with gpu-accelerated industry-standard tools.
Innovative cell and gene therapies can potentially treat and cure some of the most debilitating diseases known to humankind. But moving preclinical candidates through development, manufacturing and regulatory approval presents some distinct difficulties compared to traditional drug development.